Full Press Release Details
ENDRA Life Sciences Renews and Extends Term of
Agreement with GE Healthcare to Develop ENDRA's TAEUS
Product Targeting Non-Alcoholic Fatty Liver Disease
2018 European Launch Remains on Track with Human Data Expected in
of 2018 to Support ENDRA's First Commercial Liver
ANN ARBOR, Michigan February 5, 2018 - ENDRA Life Sciences
Inc. ( ENDRA ) (NASDAQ: NDRA), a developer of
enhanced ultrasound technologies, has renewed its
collaborative research agreement to develop ENDRA's clinical
platform, Thermo-Acoustic Enhanced UltraSound (TAEUS ),
Electric Company (NYSE: GE) acting
through its GE Healthcare unit, a leading provider of
transformational medical technologies and services, by extending
the agreement's term to January 2020.
the terms of the agreement, GE Healthcare will continue to support
ENDRA's efforts to complete commercialization of its TAEUS
technology for use in a fatty liver application by, among other
things, providing equipment and technical advice, and facilitating
introductions to GE Healthcare clinical ultrasound customers. In
return for this assistance, ENDRA will afford GE Healthcare certain
rights of first offer with respect to manufacturing and licensing
rights for the target application.
fourth quarter of 2017, ENDRA completed two major milestones
towards the commercial launch of its TAEUS clinical product in the
European Union, currently projected for the second half of
was the new partnerships with StarFish Medical and CriTech Research
to advance ENDRA's current prototype TAEUS device into a
clinical product meeting CE regulatory requirements, followed by
FDA submission for the U.S. market.
milestone was contracting with the Centre for Imaging Technology
Commercialization (CIMTEC) to commence human studies targeting
NAFLD involving both conventional ultrasound and TAEUS imaging,
along with relevant blood markers and magnetic resonance imaging
(MRI). ENDRA's objectives are to obtain important insight
into clinical work flow and TAEUS' quantitative
is off to an exciting start as evidenced by the accelerated renewal
of our collaboration agreement with GE Healthcare, the global
leader in clinical ultrasound, said Francois Michelon,
ENDRA's CEO. Based on positive market trends in the EU
and our progress achieved on the development front in 2017, we and
GE Healthcare mutually agreed to extend our partnership by two
years to continue the development and commercialization of
ENDRA's TAEUS fatty liver product in
McEathron, GE Healthcare's Vice President and General Manager
for General Imaging Ultrasound added, GE has a long history
of bringing meaningful healthcare innovation to market. We believe
that ENDRA's technology has the potential to bring
significant new capabilities to ultrasound which aligns
well with GE Healthcare's mission of increasing access to
high-quality, cost-effective healthcare. We're very excited
about completing the final steps towards commercialization of
ENDRA's TAEUS fatty liver product.
About ENDRA Life Sciences Inc.
Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA) is a developer of
enhanced ultrasound technologies. ENDRA's Photo-Acoustic Nexus-128
system is currently used by leading global medical researchers to
screen and modify disease models with high image quality and volume
scanning speed. ENDRA is developing next generation Thermo-Acoustic
Enhanced UltraSound (TAEUS ) system
to enable clinicians to visualize human tissue composition,
function and temperature in ways previously possible only with CT
& MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of
fat in the liver, for early detection and monitoring of
Non-Alcoholic Fatty Liver Disease, which affects over 1 billion
people globally, representing an estimated $13 billion global
ultrasound market opportunity. ENDRA's goal is to bring new
capabilities to ultrasound -- thereby broadening access to better
healthcare. For more information, please visit www.endrainc.com.
Forward-Looking Statements
statements in this release that are not based on historical fact
are "forward-looking statements" within the meaning of Section 27A
of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements, which are based
on certain assumptions and describe our future plans, strategies
and expectations, can generally be identified by the use of
forward-looking terms such as "believe," "expect," "may," "will,"
"should," "could," "seek," "intend," "plan," "goal," "estimate,"
"anticipate," or other comparable terms. Examples of
forward-looking statements include, among others, statements we
make regarding the continuation of our agreement with GE
Healthcare, expectations concerning ENDRA's ability to secure
regulatory approvals; anticipated product pricing; expectations
with respect to current and future partnerships, including those
with GE Healthcare, CIMTEC, StarFish and CriTech; estimates of the
timing of future events and achievements; and expectations
concerning ENDRA's business strategy. Forward-looking statements
involve inherent risks and uncertainties which could cause actual
results to differ materially from those in the forward-looking
statements, as a result of various factors including, among others,
the following: our ability to develop a commercially feasible
technology; receipt of necessary regulatory approvals; our ability
to find and maintain development partners, market acceptance of our
technology, the amount and nature of competition in our industry;
our ability to protect our intellectual property; and the other
risks and uncertainties described in ENDRA's filings with the
Securities and Exchange Commission. The forward-looking statements
made in this release speak only as of the date of this release, and
ENDRA assumes no obligation to update any such forward-looking
statements to reflect actual results or changes in expectations,